Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 57Carcinoma, Non-Small-Cell Lung 52Carcinoma, Renal Cell 38Neoplasm Metastasis 21Lung Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 17Neoplasms 17Colorectal Neoplasms 17Stomach Neoplasms 16Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 11Hodgkin Disease 11Brain Neoplasms 10Urinary Bladder Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Skin Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Sarcoma 6Colonic Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Merkel Cell 6Carcinoma, Basal Cell 6Uveal Melanoma 5

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligoprogressive × Nivolumab × 90 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡